Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices.
See omnystudio.com/listener for privacy information.
